HF
ASBPW

HRT Financial’s Aspire Biopharma Warrant ASBPW Stock Holding History

HRT Financial’s Portfolio ASBPW Stock Details ASBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-14,183
Closed – – 3443
2024
Q3 		$0 Buy
+14,183
New +$675 ﹤0.01% 3297

Other funds holding ASBPW

AC
Athos Capital Hong Kong $324M AUM 16.62% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 26.7% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.5% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

HRT Financial's ASBPW Position: Q4 2024 in Review

HRT Financial sold out of Aspire Biopharma Warrant (ASBPW) in Q4 2024, closing a stake of 14,183 shares.

HRT Financial first reported a position in ASBPW in Q3 2024 and held it in 1 quarter. The position peaked at $0 in Q3 2024. 26 funds tracked by Wall St. Rank hold ASBPW as of Q4 2024.

  • HRT Financial reported no remaining Aspire Biopharma Warrant position as of Q4 2024 after selling out during the quarter.
  • HRT Financial sold 14,183 Aspire Biopharma Warrant shares in Q4 2024.
  • HRT Financial first reported a position in Aspire Biopharma Warrant in Q3 2024 and held it in 1 quarter.
  • HRT Financial's Aspire Biopharma Warrant position peaked at $0 in Q3 2024.
  • 26 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q4 2024.

Based on HRT Financial's 13F filing for Q4 2024, filed 14 Feb 2025.